Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5–11 Years and Adolescents Aged 12–15 Years — PROTECT Cohort, July 2021–February 2022
Ashley L. Fowlkes, Sarang K. Yoon, Karen Lutrick, Lisa Gwynn, Joy Burns, Lauren Grant, Andrew L. Phillips, Katherine Ellingson, Maria V. Ferraris, Lindsay B. LeClair, Clare Mathenge, Young M. Yoo, Matthew S. Thiese, Lynn B. Gerald, Natasha Schaefer Solle, Zuha Jeddy, Leah Odame-Bamfo, Josephine Mak, Kurt T. Hegmann, Joe K. GeraldJezahel S. Ochoa, Mark Berry, Spencer Rose, Julie Mayo Lamberte, Purnima Madhivanan, Felipe A. Pubillones, Ramona P. Rai, Kayan Dunnigan, John T. Jones, Karl Krupp, Laura J. Edwards, Edward J. Bedrick, Brian E. Sokol, Ashley Lowe, Hilary McLeland-Wieser, Krystal S. Jovel, Deanna E. Fleary, Sana M. Khan, Brandon Poe, James Hollister, Joanna Lopez, Patrick Rivers, Shawn Beitel, Harmony L. Tyner, Allison L. Naleway, Lauren E.W. Olsho, Alberto J. Caban-Martinez, Jefferey L. Burgess, Mark G. Thompson, Manjusha Gaglani
Dive into the research topics of 'Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5–11 Years and Adolescents Aged 12–15 Years — PROTECT Cohort, July 2021–February 2022'. Together they form a unique fingerprint.